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Abstract
Background: The provision of clinically assisted hydration at the end of life is one of the most contentious issues
in medicine, and indeed within the general population. The reasons for contention include: a) the lack of evidence
for or against; b) the disparate opinions of healthcare professionals; and c) the generally positive opinions of
patients and their carers about clinically assisted hydration.
Methods/design: The study is a cluster randomised trial to assess the feasibility of conducting an adequately
powered, randomised controlled trial of clinically assisted hydration in patients with cancer in the last days of life.
Twelve sites, four National Health Service (NHS) hospitals and eight NHS/voluntary sector hospices in the United
Kingdom, will be randomised to give either standard intervention A: continuance of oral intake and regular mouth
care, or standard intervention B: continuance of oral intake, regular mouth care and clinically assisted hydration.
Patients will be included if they: i) have a diagnosis of cancer; ii) are aged ≥ 18 yr; iii) have an estimated prognosis
of≤ 1 week and iv) are unable to maintain sufficient oral intake (1 L per day, measured/estimated); and v) are able
to give informed consent. Patients will be excluded if they have contra-indications to receiving clinically assisted
hydration. The primary endpoint of interest is the frequency of hyperactive delirium (‘terminal agitation‘), and this
will be assessed using the Modified Richmond Agitation and Sedation Scale (administered every four hours). Other
data to be collected include the frequency of pain, respiratory secretions (‘death rattle‘), dyspnoea, nausea and
vomiting, adverse effects to clinically assisted hydration and overall survival. In addition, data will be collected on
the use of anti-psychotic drugs, sedative drugs, analgesics, anti-secretory drugs and other end-of-life medication.
The study has obtained full ethical approval.
Discussion: A randomised controlled trial of clinically assisted hydration in end-of-life care is urgently required. This
feasibility study will allow methodological and ethical issues to be understood and addressed to ensure that a
robust, adequately powered, randomised controlled trial is designed.
Trial registration: ClinicalTrials.gov NCT02344927 (registered 4 June 2014).
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Background
The provision of clinically assisted hydration (CAH) at
the end of life is one of the most contentious issues in
medicine [1, 2], and indeed within the general popula-
tion [3, 4]. The reasons for contention include: a) the
lack of evidence for/against CAH [5, 6]; b) the disparate
opinions of healthcare professionals about CAH [7]; and
c) the generally positive opinions of patients and their
carers about CAH (and the generally negative opinions
about withholding/withdrawing CAH) [7]. It is, there-
fore, unsurprising that the provision of CAH at the end
of life is extremely variable within clinical practice
(12–88 % of patients with cancer in the last week of life)
[8]. It should be noted that, in this instance, CAH refers
to the medical provision of parenteral fluids (intravenous,
subcutaneous), and not to the medical provision of enteral
fluids (such as administering fluids via a gastrostomy/
jejunostomy).
In 2012, there were 499,331 deaths registered in Eng-
land and Wales, with cancer being the most common
underlying cause of death (29 % total deaths) [9]. There
is limited data on the use of CAH in hospitals, and no
data on the use of CAH at home or in hospices (al-
though the impression is that CAH is generally not
available in the home setting, and is generally not uti-
lised in the hospice setting).
The lack of provision of fluids at the end of life was
one of the major issues raised in the recent review of the
Liverpool Care Pathway for the Dying Patient (LCP)
(which has resulted in the planned withdrawal of the
LCP in the United Kingdom) [10]. Indeed, the review
notes that “most of the submissions to the Review from
relatives and carers that were critical of the LCP made
reference to hydration and nutrition”. The review com-
ments that “if fluids are stopped without review over
many days, death from dehydration will be inevitable,
the lack of hydration having accelerated the dying
process”. However, it also highlights that “a systematic
review of all of the literature and studies evaluating the
benefits of clinically assisted hydration in palliative care
patients shows no clear benefit to either length or qual-
ity of life”. Of note, the aforementioned systematic re-
view concluded that “more evidence is needed,
particularly in relation to effects of clinically-assisted hy-
dration in patients suffering symptoms that might be
strongly influenced by hydration (e.g. delirium, and
symptoms of fluid overload)” [6].
In 2008, Good et al. conducted a Cochrane systematic
review of medically assisted hydration for adult palliative
care patients, and concluded that “currently, there are
insufficient good quality studies to make any recommen-
dations for practice with regards to the use of medically
assisted hydration in palliative care patients” [5]. Good
et al. identified five relevant studies [11–15], although
only two studies were randomised controlled studies [13,
14]. However, neither of the randomised controlled stud-
ies addressed the specific issue of the routine use of
CAH at the end of life. Thus, Cerchietti et al. included
patients with evidence of dehydration (and/or renal fail-
ure), and patients were given relatively low volumes of
fluid (1 L per day), and the fluids were only given for
48 h (and not continued until death) [13]. Similarly,
Bruera et al. only included patients with evidence of de-
hydration, and patients were given relatively low vol-
umes of fluid (1 L per day), and the fluids were only
continued for 48 h (and not continued until death) [14].
It should be noted that Good et al. re-searched the lit-
erature in early 2011, and although they did not find any
new studies, they did identify an ongoing randomised
controlled trial [16].
In 2013, Parry et al. conducted a rapid evidence review
of the literature on pathways focussed on the dying
phase in end-of-life care and their key components, and
concluded that “the current research evidence base is
not sufficient to inform specific recommendations to use
or not to use clinically-assisted nutrition and/or hydra-
tion” [6]. The review included the new randomised con-
trolled trial [16], which again did not address the
specific issue of the routine use of CAH at the end of
life. Thus, Bruera et al. only included patients with evi-
dence of dehydration, and patients were given relatively
low doses of fluid (1 L per day), and the fluids were con-
tinued for a variable duration, that is, “until the patient
was unresponsive, developed progressive coma, or died”.
The conclusion of this study was that “hydration at 1 L
per day did not improve symptoms, quality of life, or
survival”.
The purported positive effects of CAH include the
maintenance of patient comfort (for example, prevention
of thirst, prevention of dry mouth), and the maintenance
of renal perfusion/prevention of accumulation of toxins
and drugs (prevention of delirium, prevention of opioid
toxicity) [17]. In contrast, the purported negative effects
of CAH include problems due to fluid overload (for ex-
ample, worsening of peripheral oedema, worsening of
cardiac failure), and problems due to fluid-related com-
plications (for example, worsening of vomiting, worsen-
ing of respiratory secretions) [17]. In addition, it has
been claimed that ketones and other by-products of de-
hydration can have positive effects on the patients’ con-
dition/symptom control (analgesic effects, sedative
effects). As intimated above, there is little evidence to
support/refute these effects in the general population.
Patients with cancer may develop a range of problems
in the last days of life, including delirium (’terminal agi-
tation’/’terminal restlessness’ [18]), excess respiratory se-
cretions (’death rattle’), urinary retention or urinary
incontinence, and continuance or exacerbation of other
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symptoms (for example, pain, dyspnoea, nausea and
vomiting) [19].
Delirium is one of the most common problems (25–
85 % of patients) [20], and one of the most distressing
problems (for patients, relatives and healthcare profes-
sionals) [21], encountered at the end of life. Dehydration
is a recognised cause of delirium, and rehydration a
recommended intervention for delirium (in appropri-
ate situations) [20]. Nevertheless, the mainstay of the
management of delirium is the use of antipsychotic
and/or sedative drugs [20]. Such agents are used in ap-
proximately 50 % of patients in the last week of life
[22], and although they are generally very effective,
they are often associated with untoward sedation
(which necessarily impacts the dying process, espe-
cially in terms of interpersonal communication). It
should be noted that the use of sedative drugs was an-
other major issue raised in the recent review of the
LCP (which has resulted in the planned withdrawal of
the LCP in the United Kingdom) [10].
Study rationale and aim
The authors of the Cochrane systematic review dis-
cussed the need for further studies in this area, and
highlighted the barriers to conducting such studies, in-
cluding obtaining informed consent, recruitment of sub-
jects, retention of subjects, and presence of confounders
[5, 23]. Our aim is to undertake a cluster randomised
trial of clinically assisted hydration in non-dehydrated
cancer patients at the end of life (that is, in the last week
of life) in order to fully assess the practical and ethical
issues that need to be addressed in a randomised con-
trolled trial (RCT) and to provide data to adequately
power the RCT.
Methods
Trial design and setting
The study will be a multi-centre cluster randomised trial
carried out in NHS hospitals and NHS/voluntary sector
hospices in the United Kingdom. Twelve sites (four hos-
pitals, eight hospices) will participate in the feasibility
study and will be randomised to either standard treat-
ment A or standard treatment B. The Surrey Clinical
Trials Unit, Surrey CRC, University of Surrey will be re-
sponsible for the cluster randomisation, trial manage-
ment, data management and analysis.
The trial will assess the feasibility of a multi-centre
RCT by identifying and addressing the methodological
and ethical issues raised. It will provide primary and sec-
ondary endpoint data in order to design an appropriately
powered RCT.
The trial has been funded by the Research for Patient
Benefit Programme of the National Institute of Health
Research (National Health Service) and has received a
favourable ethical opinion from the London-Bromley
National Research Ethics Service (NRES) Committee
(reference 14/LO/1543), and the University of Surrey
Research Ethics Committee. The trial, current protocol,
version 5, 23 February 2015, is registered on Clinical-
Trials.gov NCT02344927 (registered 4 June 2014).
Full informed written consent will be obtained from
all patients, or their designated consultee, prior to enrol-
ment in the trial.
Oversight of trial sites
Study sites will be required to develop a cluster repre-
sentation mechanism (CRM) to represent the interests
of the cluster (and the individuals within the cluster).
The CRM has the same rights as an individual patient in
a normal randomised trial; the CRM has the right to
withdraw the cluster from the study if it decides that the
study is no longer in the interests of the cluster. The
CRM includes a Study Gatekeeper (who is responsible
for the cluster as a whole, permits the cluster taking part
in the study, and monitors the continued involvement of
the cluster in the study, for example, with a senior clin-
ician) and a Study Guardian (who is responsible for the
individuals in the cluster, permits individuals to take part
in the study, and monitors the continued involvement of
individuals in the study, for example, a senior nurse).
The CRM will be independent of the research team, and
will work to a formal document that describes the role
of the CRM.
Inclusion/exclusion criteria for participants and
recruitment
Up to 200 patients will be included in the trial. Patients
are eligible for inclusion if they have a diagnosis of
cancer; are aged 18 years or above; have an estimated
prognosis of ≤ 1 week; and are unable to maintain
sufficient oral intake (1 L per day, measured/esti-
mated). Patients will be excluded if they are clinically
dehydrated; have a relevant advance directive to re-
fuse treatment; have a clinical indication for clinically
assisted hydration (for example, hypercalcaemia);
have a clinical contra-indication to clinically assisted
hydration (for example, cardiac failure); have a clin-
ical contra-indication to peripheral cannulation; are
already being administered intravenous fluids/sub-
cutaneous fluids/total parenteral nutrition (TPN)/en-
teral feeding or fluids; have symptoms of delirium at
the time of consent or have experienced symptoms of
delirium in the previous 24 hours; or are likely to be
transferred to another setting for endof-life care (for
example, home, hospice).
Potential participants will be highlighted to the re-
search team by the clinical team; the research team will
then screen the patient for eligibility to enter the study.
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If the patient is deemed to have capacity by the clinical
team, then consent will be sought from the patient in the
normal manner by the research team Additional file 1.
If the patient is deemed not to have capacity, then a
personal consultee (that is, “someone who has a role in
caring for the person who lacks capacity or is interested
in that person’s welfare but is not doing so for remuner-
ation or acting in a professional capacity”) will be
approached for advice re the patient entering the study
[24, 25]. In this study, the personal consultee could be a
relation of the person or a friend of the person. The per-
sonal consultee will be given an information sheet about
the study, given the opportunity to ask questions about
the study, and asked whether in their opinion the patient
would have any objection to taking part in the study.
If the patient is deemed not to have capacity, and no
personal consultee is available, then a nominated con-
sultee will be approached for advice re the patient enter-
ing the study [24, 25]. In this study, the nominated
consultee will be the Study Guardian (who is independ-
ent of the research team).
Interventions
The interventions utilised within this trial represent
current standards of care within clinical practice. Sites
will be randomised to either ’standard intervention arm
A‘ or ’standard intervention arm B‘, and this will become
the standard of care within the site for the duration of
this trial.
Standard intervention arm A involves:
 Continuance of oral intake (if appropriate)
 Regular ’mouth care’
 Standard management of pain and other symptoms
in the terminal phase
Standard intervention arm B involves:
 Continuance of oral intake (if appropriate)
 Regular ’mouth care’
 Standard management of pain and other symptoms
in the terminal phase
 Clinically assisted hydration, that is, parenteral fluids
Mouth care should be performed at least every four
hours, and should correspond to the participating site’s
policy/procedures for oral care in the terminal phase.
Mouth care should be discontinued if it causes distress/
discomfort to the patient.
The parenteral fluids may be administered either intra-
venously or subcutaneously at the discretion of the med-
ical and nursing team [26]. The type of fluid to be
administered is dextrose saline (4 % dextrose, 0.18 %
sodium chloride), and the volume to be administered
will be dependent on the patient's weight [27] Table 1.
Study procedures
During the treatment period patients will be reviewed at
least every four hours, and an assessment made as to
whether or not certain symptoms are present, that is,
hyperactive delirium (‘terminal agitation‘), pain, excess
respiratory secretions (‘death rattle‘), nausea and vomit-
ing, dyspnoea and urinary continence. Agitation will be
given a score (see below), but the other symptoms will
simply be recorded as present or absent. In addition,
changes in regular medications, use of as required
(PRN) medications, oral intake, urinary continence, and
(if appropriate) parenteral fluids administered, adverse
events relating to parenteral fluids and requirements for
re-cannulation will also be noted. Data will be obtained
from the participant’s observation chart and the partici-
pant’s drug chart(s); these documents are considered
source documents in this study.
At the end of the study the researcher will record the
participant’s outcome, including the date of death/with-
drawal, and the reason for withdrawal (if appropriate).
The end of study occurs when an individual participant
either: a) survives for ≥ 14 days; b) dies (expected out-
come); or c) is withdrawn from the study Table 2.
Outcome measures
Observation chart data
The primary outcome will be the frequency of hyper-
active delirium (‘terminal agitation‘), assessed using the
modified Richmond Agitation and Sedation Scale
(mRASS) [28]. The mRASS is a numerical scale that in-
cludes four levels of agitation: +1 = restless; +2 = agi-
tated; +3 = very agitated; and +4 = combative. It should
be noted that patients with pain/other problems may ap-
pear agitated, and so a diagnosis of hyperactive delirium
(terminal agitation) must be validated by the clinical
team’s use of an appropriate anti-psychotic or sedative
drug to treat delirium (terminal agitation).
Other, secondary endpoints will be obtained through
the observation chart, including oral intake, problems
relating to parenteral fluids and any change in CAH
status.
Table 1 Standard treatment B: volume of fluid to be
administered
Patient’s weight Volume of fluid
<45 kg 1 L/24 h
45–60 kg 1.5 L/24 h
>60 kg 2 L/24 h
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Process evaluation
A process evaluation will be undertaken in parallel to
the feasibility study using a framework developed for
cluster randomised trials [29] (based on the so-called
RE-AIM framework [30]): data will be derived from rou-
tine research governance/trial monitoring (quantitative
data) and additional/independent assessments (quantita-
tive data, qualitative data). Thus, Principal Investigators
from all units will be asked to complete a specifically de-
veloped questionnaire about the study processes at 1, 3
and 12 months after the start of the study (primarily
quantitative data). In addition, clinical staff from 50 % of
the units (randomly selected) will be asked to participate
in focus groups about the study processes at 3–6 months
after the start of the study (qualitative data).
Data management
Investigator site staff will enter trial data into a paper
CRF. The paper CRF is an Annotated Study Book
(printed copy of the study eCRF) that has been reviewed
by key trial staff including the Chief Investigator, Study
Statistician and Trial Project Manager. Once the moni-
tor has visited the site and completed the monitoring
visit, completed pages will be stripped and returned to
Surrey CTU for data entry into the eCRF. An eCRF will
be set up in accordance with the protocol by a Data
Manager and reviewed by another Data Manager, with
range checks at point of entry and edit checks.
Point of entry checks fire during data entry, to reduce
data entry errors. Range and edit checks will be exam-
ined by a Data Manager and queries generated as appro-
priate. Queries raised will be tracked by sending queries
from and receiving answers to a Data Management mail-
box. Surrey CRC will then update as appropriate.
Statistical consideration
Sample size
Twelve sites (four hospitals, eight hospices) will be in-
volved in the feasibility study, and these will be rando-
mised to either standard intervention A or standard
intervention B. There will be a separate randomisation
process for the hospitals and the hospices. The target is
to recruit 200 participants from the 12 sites within a
period of one year; the end of the trial will occur when
either 200 participants have been recruited, or the trial
has been ongoing for one year (and inadequate numbers
of participants have been recruited).
Analysis
A ’case‘ of hyperactive delirium is considered to be a par-
ticipant that scores +2 to +4 on the mRASS [28], and is
treated by the clinical team with an appropriate anti-
psychotic or sedative drug to treat hyperactive delirium
(terminal agitation). Participants who do not fall into
this category will be considered as ’non-case‘. This di-
chotomous outcome will be used as the primary end-
point for the analysis.
The analysis evaluating the difference in proportions
of participants experiencing hyperactive delirium be-
tween the two interventions will be a logistic regression
with the occurrence of hyperactive delirium as the
dependent variable and interventions (A or B), cluster
and cluster type (hospital or hospice) as explanatory var-
iables. The analysis will be based on the intention-to-
treat (ITT) population, and will furnish estimates of the
proportion of subjects suffering from hyperactive delir-
ium for each intervention together with an estimate of
the coefficient of variation of true proportions between
clusters within each intervention arm. The latter of these
estimates is an important requirement for determining
the sample size aspect of a future cluster randomised
study designed with adequate power to evaluate the im-
pact of the intervention including CAH. It is judged that
recruitment of 200 participants in 12 clusters in the
feasibility study will provide a realistic estimate.
The logistic regression analysis will allow the testing of
the hypothesis of no difference in the proportion of
hyperactive delirium experienced between groups
treated by either intervention. The intervention includ-
ing CAH will be considered an improvement on the
other intervention, in this and any future definitive
Table 2 Overview of study assessments
Assessments Screening Treatment period
(daily assessments)
End of
study
Inclusion/exclusion criteria X
Consent X
Demographic data X
Cancer diagnosis X
Concurrent medical history X
Regular medication X X
Oral intake X X
Urinary continence X X
4 hourly Modified Richmond
Agitation - Sedation Scale scores
X
4 hourly symptom occurrences X
As required medication X
Oral intake X
Urinary continence X
Parenteral fluids administered X
Adverse events X
Cannulation problems X
Participant outcome X
Davies et al. Trials  (2015) 16:464 Page 5 of 8
study, only if the proportion of hyperactive delirium suf-
ferers is reduced by at least 20 %.
It is considered unlikely that this statistical analysis of
the feasibility study will be able to test this hypothesis
with sufficient power, but its results, together with infor-
mation gained from other aspects of the study manage-
ment, will be used to design a definitive study.
From a statistical perspective, the estimates of the pro-
portion of subjects suffering hyperactive delirium for
each intervention, and the coefficient of variation of true
proportions between clusters within each intervention,
obtained from the feasibility study, will be used to deter-
mine the number of clusters and sample size necessary
to detect a difference of 20 % in the proportion of hyper-
active delirium sufferers between the interventions with
80 % power using a two-sided 5 % significance level.
This calculation will form part of the design of the de-
finitive study.
Should the number of clusters and sample size in the
feasibility study retrospectively be found to provide the
necessary power to test the hypothesis, the statistician
will provide this information to the study team as input
into their decision as to whether a definitive study is
required.
Governance
Safety reporting
All adverse events (AEs) and serious adverse events
(SAEs) will be documented in the CRF, and reviewed by
the Chief Investigator and Trial Monitoring Committee
(TMC). As the study is being undertaken in patients in
the last days of life, the progression of existing problems
and the development of routine end-oflife problems (for
example, hyperactive delirium/’terminal agitation‘, excess
respiratory secretions/’death rattle‘) are not considered
to be SAEs.
Monitoring
The Surrey CTU, Surrey CRC were responsible for the
management and coordination of the clinical trial, in-
cluding communication of important protocol modifica-
tions to trial investigators and trial sites. The Surrey
CTU will monitor trial sites on a regular basis to ensure
adherence to Good Clinical Practice, and especially com-
pliance with the protocol. The monitor will inspect the
site file and will check the recruitment/screening log
and source documents.
Trial Monitoring Committee
The study will have a Trial Monitoring Committee
(TMC), which will consist of an independent Chairper-
son (Consultant in Palliative Medicine), the Chief Inves-
tigator, the Clinical Trial Unit Lead, the Lead Research
Nurse, the Statisticians, the Ethical Advisor, patient/
carer representatives and one of the Principal Investiga-
tors. The TMC will meet approximately once a quarter
(until the end-of-study report has been completed). The
TMC will review all aspects of the study, particularly
any safety issues.
Confidentiality
The study will conform to the Data Protection Act (and
related legislation); all data will be treated as confiden-
tial, and data will be anonymised prior to removal from
the study site.
Publication and dissemination
At the end of the study, a study report will be written
and submitted to the funder, the Sponsor, the REC and
the Principal Investigators.
The results of the study will be published in an appro-
priate medical journal and presented at appropriate
medical conferences. The main publication will be
authored by the Chief Investigator with contribution
from the Surrey CTU. Upon completion of the Clinical
Trial, or when the Clinical Trial data are adequate (in
the Sponsor’s reasonable judgement), an Investigator site
may prepare the data deriving from the Clinical Trial for
publication. Such data will be submitted to the Sponsor
and Chief Investigator for review and comment prior to
publication.
Discussion
The provision of clinically assisted hydration (CAH) at
the end of life is one of the most contentious issues in
medicine [1, 2], and indeed within the general popula-
tion [3, 4]. In some instances there is a clear indication
for giving CAH (such as for a patient with opioid tox-
icity), whilst in other instances there is a clear indication
for not giving CAH (for example, in a patient with car-
diac failure). Currently, however, it is impossible to make
a best interests decision for the majority of patients (due
to a lack of evidence). Hence, there is an urgent need/
ethical necessity to undertake research to define the role
of CAH in the last days of life (and indeed the role of
mouth care in the last days of life).
The study interventions to be used in the trial are rou-
tinely used in clinical practice, and so all of the patients
will receive a ’standard intervention‘ (and not an experi-
mental treatment, or a placebo treatment). Indeed any
patients who require a specific intervention or for whom
CAH is contra-indicated will not be considered eligible
for the trial.
The study team is mindful that the trial involves pa-
tients in the last week of life, and it is anticipated that
many of the potential participants will be unable to pro-
vide informed consent (due to impaired cognition/im-
paired consciousness). As the study is not a Clinical
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Trial of an Investigational Medicinal Product (CTIMP),
the study comes under the remit of the Mental Capacity
Act [24, 25]. Consent will be sought from the patient
(whenever possible), or advice sought from a ’personal
consultee‘ (when the patient is unable to provide con-
sent), or advice from a ’nominated consultee‘ (when the
patient is unable to provide consent, and there is no per-
sonal consultee). In this study the personal consultee will
be a relation or friend of the patient, and the nominated
consultee will be the Study Guardian. It is hoped that
this trial will allow a definitive study to be performed of
the utility/role of CAH in patients with cancer in the last
days of life.
Trial status
Patient recruitment commenced on 20 February 2015.
Additional file
Additional file 1: Patient information sheet. Information regarding
the study to enable patients or their designee to make a decision
as to whether they wish to participate in the trial. (DOCX 63 kb)
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